[go: up one dir, main page]

WO2003027276A3 - Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies - Google Patents

Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies Download PDF

Info

Publication number
WO2003027276A3
WO2003027276A3 PCT/IB2002/004134 IB0204134W WO03027276A3 WO 2003027276 A3 WO2003027276 A3 WO 2003027276A3 IB 0204134 W IB0204134 W IB 0204134W WO 03027276 A3 WO03027276 A3 WO 03027276A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoma
leukemia
diagnosis
treatment
methods
Prior art date
Application number
PCT/IB2002/004134
Other languages
English (en)
Other versions
WO2003027276A2 (fr
Inventor
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Anne Ahlmann Nielsen
Helle Moving
Original Assignee
Univ Aarhus
Finn Skou Pedersen
Annette Balle Sorensen
Javier Martin Hernandez
Anne Ahlmann Nielsen
Helle Moving
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/962,916 external-priority patent/US20030077590A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Application filed by Univ Aarhus, Finn Skou Pedersen, Annette Balle Sorensen, Javier Martin Hernandez, Anne Ahlmann Nielsen, Helle Moving filed Critical Univ Aarhus
Priority to AU2002337442A priority Critical patent/AU2002337442A1/en
Publication of WO2003027276A2 publication Critical patent/WO2003027276A2/fr
Publication of WO2003027276A3 publication Critical patent/WO2003027276A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouvelles séquences destinées à être utilisées pour diagnostiquer et traiter des lymphomes et des leucémies. L'invention concerne par ailleurs l'utilisation de nouvelles compositions dans des méthodes de criblage.
PCT/IB2002/004134 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies WO2003027276A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002337442A AU2002337442A1 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US09/962,854 2001-09-24
US09/962,929 2001-09-24
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/963,131 2001-09-24
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,855 2001-09-24
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/962,916 2001-09-24

Publications (2)

Publication Number Publication Date
WO2003027276A2 WO2003027276A2 (fr) 2003-04-03
WO2003027276A3 true WO2003027276A3 (fr) 2004-02-12

Family

ID=27542309

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1
PCT/IB2002/004134 WO2003027276A2 (fr) 2001-09-24 2002-09-24 Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/IB2002/004158 WO2003027321A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a une expression alteree de neurogranine
PCT/IB2002/004197 WO2003027295A2 (fr) 2001-09-24 2002-09-24 Procedes de diagnostic et de traitement de maladies associees a l'expression alteree de la jak1
PCT/IB2002/004123 WO2003027320A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de pik3r1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005830 WO2003043565A2 (fr) 2001-09-24 2002-09-24 Methodes de diagnostic et de traitement de maladies associees a l'expression modifiee de nrf2

Country Status (2)

Country Link
AU (4) AU2002337442A1 (fr)
WO (5) WO2003027321A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005879A2 (fr) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions et procedes pour traiter ou prevenir des troubles associes au stress oxydatif
US20090215876A1 (en) * 2006-02-14 2009-08-27 King Randall W Mitotic Progression Genes and Methods of Modulating Mitosis
WO2020247914A1 (fr) * 2019-06-07 2020-12-10 Emory University Mutant g12v de kras se liant à jak1, inhibiteurs, compositions pharmaceutiques et procédés associés

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016430A1 (fr) * 1990-04-13 1991-10-31 Research Development Foundation NOUVEAUX CLONES D'ANDc DE LYMPHOCYTES T DE LYMPHOME
WO1993015221A1 (fr) * 1992-01-29 1993-08-05 Hitachi Chemical Co., Ltd. Procede de mesure de l'arn messager
WO1998016557A1 (fr) * 1996-10-11 1998-04-23 The General Hospital Corporation Dosages pour recepteurs lies a la proteine g
WO1999054448A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique provenant d'un fibrome uterin
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO2001000861A1 (fr) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Modulation anti-sens de l'expression de g-alpha-s1
WO2001007617A1 (fr) * 1999-07-22 2001-02-01 Knoll Gmbh Homologue humain de la proteine secretoire neuroendocrine bovine, nesp55, polynucleotides et utilisations associees liees a l'obesite
WO2002022882A2 (fr) * 2000-09-13 2002-03-21 Archemix Corporation Biocapteur d'acide nucleique active par une cible et ses procedes d'utilisation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
JP2000506396A (ja) * 1996-11-01 2000-05-30 オニックス ファーマシューティカルズ，インコーポレイティド ホスファチジルイノシトール―３′―キナーゼ関連タンパク質をコードするヌクレオチド配列及びその利用
AU742342B2 (en) * 1997-05-21 2001-12-20 Clontech Laboratories, Inc. Nucleic acid arrays
EP1053319A2 (fr) * 1998-01-28 2000-11-22 Chiron Corporation Genes humains et expression de produits genetiques ii
IL137939A0 (en) * 1998-02-23 2001-10-31 Quark Biotech Inc P53-dependent secretion of growth inhibitory factors
MXPA00010150A (es) * 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
WO1999065928A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Population de polynucleotides isoles de tissus mammaires tumoraux metastatiques ou non metastatiques
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
CA2358086A1 (fr) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Interactions proteine-proteine dans les troubles neurodegeneratifs
AU779908B2 (en) * 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001030973A2 (fr) * 1999-10-25 2001-05-03 Princeton University Sequences genetiques associees a la proliferation et aux pathologies des cellules neuronales
AU1760201A (en) * 1999-11-12 2001-06-06 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening foractive agents
AU2630801A (en) * 2000-01-07 2001-07-24 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
IL151079A0 (en) * 2000-02-07 2003-04-10 Quark Biotech Inc Fas pathway genes
PT3029041T (pt) * 2000-04-25 2020-05-13 Icos Corp Inibidores de fosfatidil-inositol 3-quinase delta humana
EP1277754B8 (fr) * 2000-04-27 2005-09-28 Astellas Pharma Inc. Derives d'imidazopyridine
AU2001269766A1 (en) * 2000-06-09 2001-12-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
AU2001290699A1 (en) * 2000-09-08 2002-03-22 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
CA2422314A1 (fr) * 2000-09-12 2002-03-21 Transgenetics Incorporated Organisation en micro-reseaux de genes cibles de facteur de transcription
WO2002040637A2 (fr) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Modulation antisens de l'expression de pi3k p85
WO2002059367A2 (fr) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Jeu de microechantillons de diagnostic pour ibd, maladie de crohn et colite ulcereuse
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
EP1363702A4 (fr) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Procedes d'inhibition de kinases
CA2439854A1 (fr) * 2001-03-01 2002-09-12 Epigenomics Ag Procede de mise au point de groupes d'echantillons de genes a des fins de diagnostic et de therapie qui sont bases sur l'expression et l'etat de methylation des genes
CA2459219A1 (fr) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016430A1 (fr) * 1990-04-13 1991-10-31 Research Development Foundation NOUVEAUX CLONES D'ANDc DE LYMPHOCYTES T DE LYMPHOME
WO1993015221A1 (fr) * 1992-01-29 1993-08-05 Hitachi Chemical Co., Ltd. Procede de mesure de l'arn messager
WO1998016557A1 (fr) * 1996-10-11 1998-04-23 The General Hospital Corporation Dosages pour recepteurs lies a la proteine g
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
WO1999054448A2 (fr) * 1998-04-17 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Sequences d'acide nucleique provenant d'un fibrome uterin
WO2001000861A1 (fr) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Modulation anti-sens de l'expression de g-alpha-s1
WO2001007617A1 (fr) * 1999-07-22 2001-02-01 Knoll Gmbh Homologue humain de la proteine secretoire neuroendocrine bovine, nesp55, polynucleotides et utilisations associees liees a l'obesite
WO2002022882A2 (fr) * 2000-09-13 2002-03-21 Archemix Corporation Biocapteur d'acide nucleique active par une cible et ses procedes d'utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HALLEK M ET AL: "REDUCED RESPONSIVENESS OF ADENYLATE CYCLASE TO FORSKOLIN IN HUMAN LYMPHOMA CELLS", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 42, no. 7, 1991, pages 1329 - 1334, XP008011750, ISSN: 0006-2952 *
HAYWARD B E ET AL: "AN IMPRINTED ANTISENSE TRANSCRIPT AT THE HUMAN GNAS1 LOCUS", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 9, no. 5, 22 March 2000 (2000-03-22), pages 835 - 841, XP000946068, ISSN: 0964-6906 *
KLEMKE MARTIN ET AL: "Characterization of the extra-large G protein alpha-subunit XLalphas. II. Signal transduction properties.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 43, 27 October 2000 (2000-10-27), pages 33633 - 33640, XP002247467, ISSN: 0021-9258 *
LAZAREVIC M B ET AL: "Glucocorticoid-altered G protein alpha subunit expression in jurkat lymphoma cells.", CLINICAL RESEARCH, vol. 42, no. 2, 1994, Meeting of the American Federation for Clinical Research;Baltimore, Maryland, USA; April 29-May 2, 1994, pages 311A, XP008019515, ISSN: 0009-9279 *
MATTERA R ET AL: "IDENTIFICATION BY MOLECULAR CLONING OF TWO FORMS OF THE ALPHA-SUBUNIT OF THE HUMAN LIVER STIMULATORY G-S REGULATORY COMPONENT OF ADENYLYL CYCLASE", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 206, no. 1, 1986, pages 36 - 42, XP001159666, ISSN: 0014-5793 *
PFEILSTOECKER M ET AL: "Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34.", AMERICAN JOURNAL OF HEMATOLOGY, vol. 64, no. 3, July 2000 (2000-07-01), pages 156 - 160, XP008019516, ISSN: 0361-8609 *
RALL T ET AL: "IDENTIFICATION OF THE LESION IN THE STIMULATORY GTP-BINDING PROTEIN OF THE UNCOUPLED S49 LYMPHOMA", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS, vol. 224, no. 2, 1987, pages 365 - 371, XP001159774, ISSN: 0014-5793 *
WEISS U ET AL: "NEUROENDOCRINE SECRETORY PROTEIN 55 (NESP55): ALTERNATIVE SPLICING ONTO TRANSCRIPTS OF THE GNAS GENE AND POSTTRANSLATIONAL PROCESSING OF A MATERNALLY EXPRESSED PROTEIN", NEUROENDOCRINOLOGY, S.KARGER, BASEL, CH, vol. 71, no. 3, 2000, pages 177 - 186, XP000938251, ISSN: 0028-3835 *
WROE STEPHANIE F ET AL: "An imprinted transcript, antisense to Nesp, adds complexity to the cluster of imprinted genes at the mouse Gnas locus.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 7, 28 March 2000 (2000-03-28), March 28, 2000, pages 3342 - 3346, XP000938372, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002329000A1 (en) 2003-04-07
WO2003027320A3 (fr) 2003-10-23
AU2002364889A1 (en) 2003-06-10
AU2002330713A1 (en) 2003-04-07
WO2003043565A2 (fr) 2003-05-30
WO2003027276A2 (fr) 2003-04-03
AU2002364889A8 (en) 2003-06-10
WO2003027295A2 (fr) 2003-04-03
WO2003027321A2 (fr) 2003-04-03
WO2003027321A3 (fr) 2003-11-06
WO2003027320A2 (fr) 2003-04-03
AU2002337442A1 (en) 2003-04-07
WO2003027295A3 (fr) 2003-10-16
WO2003043565A3 (fr) 2003-11-13

Similar Documents

Publication Publication Date Title
WO2003008583A3 (fr) Nouvelles compositions et methodes relatives au cancer
EP2014669A3 (fr) Procédés et compositions de lutte contre le cancer
WO2003045230A3 (fr) Compositions et procedes contre le cancer
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
WO2003000200A3 (fr) ss-2'-OU 3'-HALONUCLEOSIDES
WO2005011592A3 (fr) Indazoles-o-glucosides substitues
WO2005012243A3 (fr) Indole-o-glucosides substitues
EP2772254A3 (fr) Nouveaux agents antibactériens
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
GB0111186D0 (en) Novel compounds
SG167670A1 (en) Aminocyclohexyl ether compounds and uses thereof
WO2003057146A3 (fr) Compositions et procedes concernant le cancer
WO2003053224A3 (fr) Nouvelles compositions et methodes contre le cancer
WO2004087073A3 (fr) Traitement d'etats de demyelinisation
WO2002081745A3 (fr) Genes impliques dans l'osteogenese et procedes d'utilisation associes
WO2002024867A3 (fr) Nouvelles compositions et nouvelles methodes pour le diagnostic et le traitement des lymphomes et des leucemies
IL175369A0 (en) Novel compound, corresponding compositions, preparation and/or treatment methods
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
WO2003035837A3 (fr) Nouvelles compositions et procedes relatifs au cancer
CA2436572A1 (fr) Perylenequinones utilisees comme photosensibilisants et sonosensibilisants
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2003039484A3 (fr) Nouvelles compositions et methodes pour le traitement du cancer
WO2004045545A3 (fr) Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer
WO2003071933A3 (fr) Nouvelles compositions et procedes de traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP